NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

352.55 -12.65 (-3.46%)

6.2M NSE+BSE Volume

NSE 02 Apr, 2026 3:31 PM (IST)

57,145.1

Market Cap

Market Leader

Beta 1Year

Average volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Search Inside the pdf :

Biocon Ltd.

16 Feb 2026

352.55

-3.46%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock

Biocon Ltd. has an average target of 398.80 from 5 brokers.

Biocon Ltd.

13 Feb 2026

352.55

-3.46%

Temporary constraints weigh on performance

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) delivered lower-than-expected financial performance for the quarter. Temporary constraints in the biologics and CRDMO segments impacted revenue for the quarter.

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

02 Jan 2026, 12:00AM

352.55

-3.46%

BIOCON LTD

Accumulate: Biocon Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Biocon Ltd is a biopharmaceutical company that develops therapies for chronic diseases such as autoimmune, cancer and diabetes. The company has developed and introduced novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogues. Consolidated revenue in Q2FY26 increased 19.6% YoY to Rs. 4,296cr aided by...

Biocon Ltd. has an average target of 398.80 from 5 brokers.

Biocon Ltd.

10 Dec 2025

352.55

-3.46%

Biocon Ltd.

Sell: Biocon Ltd.

Recommendation Target

ICICI Direct

announced to acquire entire minority shareholder stake of 23.3% in Biocon Biologics held by Viatris (Mylan Inc.), Serum Institute, True North and Tata Capital for US$ 1.173 billion, making it a wholly-owned subsidiary and valuing BBL at US$ 5.5 billion. Biocon will issue its shares worth US$ 773 million and make a cash payment to Viatris for the balance US$ 400 million. Cash payment to be paid by bridge / interim funding and a...

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

08 Dec 2025

352.55

-3.46%

Integration to bring scale and clarity

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) is fully integrating Biocon Biologics (BBL) by acquiring the remaining stake of 23.3%. In addition to the share swap, BIOS is raising additional capital through a QIP of up to INR45b, subject to shareholder approval, for the cash component payable to Viatris.

Biocon Ltd. has an average target of 398.80 from 5 brokers.

Biocon Ltd.

29 Nov 2025

352.55

-3.46%

Pick of the Week:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

BUY with a target price of Rs 440, implying an upside of ~10% from the CMP.

Number of FII/FPI investors increased from 308 to 347 in Dec 2025 qtr.

Biocon Ltd.

14 Nov 2025

352.55

-3.46%

Launches boost growth; profitability improvement tepid

Sell: Biocon Ltd.

Target

ICICI Securities Limited

Biocon’s Q2FY26 revenue growth of 19.6% YoY was driven by recent launches like bUstekinumab, bAspart, bBevacizumab and bAflibercept, and the launch of generic liraglutide.

Biocon Ltd. has an average target of 398.80 from 5 brokers.

Biocon Ltd.

13 Nov 2025

352.55

-3.46%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

we maintain a BUY rating on the stock.

Number of FII/FPI investors increased from 308 to 347 in Dec 2025 qtr.

Biocon Ltd.

12 Nov 2025

352.55

-3.46%

Operationally in-line 2Q; healthy growth in core business

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) delivered in-line revenue/EBITDA for 2QFY26. PAT for the quarter was better than expected, driven by lower minority interest for the quarter.

Number of FII/FPI investors increased from 308 to 347 in Dec 2025 qtr.

Biocon Ltd.

03 Oct 2025, 12:00AM

352.55

-3.46%

BIOCON LTD

Sell: Biocon Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Biocon Ltd is a biopharmaceutical company that develops therapies for chronic diseases such as autoimmune, cancer and diabetes. The company has developed and introduced novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogues. In Q1FY26, Biocon's consolidated revenue grew 14.8% YoY to Rs. 3,942cr, driven...

Number of FII/FPI investors increased from 308 to 347 in Dec 2025 qtr.

Is Biocon Ltd. worth buying?

738 Votes:

Buy 74.8%

Sell 16.4%

Hold 8.81%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf